Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ (DCIS) Patient Population at Low-risk of Upgrade to Invasive Carcinoma?

被引：0
|
作者：
Pilewskie, M. [1 ]
Stempel, M. [1 ]
Rosenfeld, H. [1 ]
Eaton, A. [1 ]
Van Zee, K. J. [1 ]
Morrow, M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
下载
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [1] Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
    Melissa Pilewskie
    Michelle Stempel
    Hope Rosenfeld
    Anne Eaton
    Kimberly J. Van Zee
    Monica Morrow
    Annals of Surgical Oncology, 2016, 23 : 3487 - 3493
  • [2] Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
    Pilewskie, Melissa
    Stempel, Michelle
    Rosenfeld, Hope
    Eaton, Anne
    Van Zee, Kimberly J.
    Morrow, Monica
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (11) : 3487 - 3493
  • [3] Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
    Tawakalitu O. Oseni
    Barbara L. Smith
    Constance D. Lehman
    Charmi A. Vijapura
    Niveditha Pinnamaneni
    Manisha Bahl
    Annals of Surgical Oncology, 2020, 27 : 4459 - 4465
  • [4] Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
    Oseni, Tawakalitu O.
    Smith, Barbara L.
    Lehman, Constance D.
    Vijapura, Charmi A.
    Pinnamaneni, Niveditha
    Bahl, Manisha
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (11) : 4459 - 4465
  • [5] Treating low-risk Ductal Carcinoma in Situ (DCIS) ... or not? Qualitative study of patient perspectives
    Hersch, Jolyn
    Nickel, Brooke
    Dixon, Ann
    Houssami, Nehmat
    Saunders, Christobel
    Jansen, Jesse
    Rutherford, Claudia
    Barratt, Alexandra
    Spillane, Andrew
    Wylie, Liz
    Stuart, Kirsty
    Robertson, Geraldine
    McCaffery, Kirsten
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 122 - 122
  • [6] Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma
    Lamb, Leslie R.
    Lehman, Constance D.
    Oseni, Tawakalitu O.
    Bahl, Manisha
    ACADEMIC RADIOLOGY, 2020, 27 (10) : 1394 - 1399
  • [7] Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma
    Lamb, Leslie R.
    Kim, Geunwon
    Oseni, Tawakalitu O.
    Bahl, Manisha
    ACADEMIC RADIOLOGY, 2021, 28 (03) : e71 - e76
  • [8] Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial
    Daniel Rea
    Adele Francis
    Matthew Wallis
    Jeremy Thomas
    John Bartlett
    Sarah Bowden
    David Dodwell
    Lesley Fallowfield
    Claire Gaunt
    Andrew Hanby
    Valerie Jenkins
    Lucy Matthews
    Sarah Pinder
    Sarah Pirrie
    Malcolm Reed
    Margaret Wilcox
    Tracy Roberts
    Cliona Kirwan
    Cassandra Brookes
    Patricia Fairbrother
    Lucinda Billingham
    Andrew Evans
    Jennie Young
    Annals of Surgical Oncology, 2017, 24 : 566 - 567
  • [9] How patient advocates and researchers work together in PRECISION* to identify low-risk ductal carcinoma in situ (DCIS) that may not need aggressive treatment
    Collyar, Deborah
    Pinto, Donna
    Stobart, Hilary
    Verschuur, Ellen
    van Oirsouw, Marja
    CANCER RESEARCH, 2020, 80 (04)
  • [10] How patient advocates and researchers work together in PRECISION* to identify low-risk ductal carcinoma in situ (DCIS) that may not need aggressive treatment
    Collyar, Deborah
    Pinto, Donna
    Stobart, Hilary
    Verschuur, Ellen
    van Oirsouw, Marja
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 541 - 541
12345